Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | M1774 + Peposertib |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
M1774 | M-1774|M 1774|tuvusertib | ATR Inhibitor 16 | M1774 inhibits ATR, potentially resulting in decreased tumor growth (PMID: 38407317). | |
Peposertib | M3814|M-3814|Nedisertib|MSC2490484A | DNA_PK Inhibitor 9 | Peposertib (MSC2490484A) is a DNA-dependent protein kinase (DNA-PK) inhibitor that blocks DNA damage repair, which may lead to antitumor activity by sensitizing cancer cells to radiation and agents that induce DNA double strand breaks (PMID: 32220971). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05687136 | Phase I | M1774 + Peposertib | Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and M1774 for Advanced Solid Tumors | Recruiting | USA | 0 |